Roche inks $50M ADC pact with Chinese biotech as field’s flurry spills over into 2024

Antibody-drug conjugates, one of the creams of the crop in 2023 biopharma dealmaking, are riding into 2024 on a strong note as Roche pays $50 million upfront to collaborate with a biotech in China, where many of the ADC deals have been made recently.

The Swiss Big Pharma is pairing up with Suzhou-based MediLink Therapeutics, which teamed with BioNTech last fall for $70 million upfront and with Zai Lab last April for an undisclosed amount.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

How Trump’s approach to regulating AI in health care could diverge from Biden’s

A lot has happened with artificial intelligence since President-elect Donald Trump was last in the White House. Nudged into action by the advent of generative

November 8, 2024

Aficamten improves exercise tolerance in patients with HOCM

Exercise intolerance is often severe among patients with cardiovascular disease and can impose significant limitations on their physical abilities and quality of life. Medications known

September 5, 2024

Signia Launches Advanced Prescription-Grade Earbuds

What You Should Know: – Committed to helping hearing care professionals (HCPs) empower people with its breakthrough Integrated Xperience (IX) hearing aid platform, hearing aid innovator

September 4, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.